[血清唾液酸化Tn抗原作为上皮性卵巢癌患者的预后标志物]

[Serum sialyl Tn antigen as a prognostic marker in patients with epithelial ovarian cancer].

作者信息

Kobayashi H, Terao T, Kawashima Y

机构信息

Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine.

出版信息

Nihon Sanka Fujinka Gakkai Zasshi. 1992 Jan;44(1):14-20.

PMID:1541859

Abstract

Circulating serum sialyl Tn (STN) antigen levels were measured in 89 patients with epithelial ovarian cancer, 157 benign disease, and in 126 healthy controls. Serum antigen levels were increased in 48.3% of patients with ovarian cancer. The false positive rate is significantly low (4.0% in healthy controls and 9.6% in benign disease). The levels of STN antigen were significantly higher in sera of patients with cancer than in those in benign and healthy controls (p less than 0.05). The rise in serum STN antigen levels correlated to the size of the primary tumors. Of the histological type, it is interesting to note the high sensitivity in mucinous-type ovarian cancer. Survival at 1, 2, 3, 4 and 5 years for patients with STN-negative (serum STN levels less than 50 U/ml) versus STN-positive (serum STN levels greater than or equal to 50 U/mol) was 96.2, 92.3, 86.5, 82.7, and 76.9% versus 59.5, 29.7, 18.9, 10.8, and 10.8%, respectively (p less than 0.05). The overall survival probability was worse in patients with STN-positive sera. Percent progression-free survival at 1, 2, 3, 4 and 5 years for patients with STN-negative versus STN-positive was 90.4, 86.5, 76.9, 59.6, and 51.9% versus 35.1, 16.2, 8.1, 8.1, and 5.4%, respectively (p less than 0.05). The overall progression-free period of survival was shorter in patients with STN-positive sera. Multivariate regression analysis revealed that positive STN, stage, PS and histologic grade were the four variables of most importance in predicting survival. These results indicate that a positive STN antigen level in sera is an independent predictor of poor prognosis in ovarian cancer.

摘要

对89例上皮性卵巢癌患者、157例良性疾病患者及126例健康对照者测定了循环血清唾液酸Tn（STN）抗原水平。48.3%的卵巢癌患者血清抗原水平升高。假阳性率显著较低（健康对照者为4.0%，良性疾病患者为9.6%）。癌症患者血清中STN抗原水平显著高于良性疾病患者和健康对照者（p<0.05）。血清STN抗原水平的升高与原发性肿瘤的大小相关。在组织学类型方面，值得注意的是黏液性卵巢癌的高敏感性。STN阴性（血清STN水平低于50 U/ml）与STN阳性（血清STN水平大于或等于50 U/mol）患者的1年、2年、3年、4年和5年生存率分别为96.2%、92.3%、86.5%、82.7%和76.9%，而STN阳性患者分别为59.5%、29.7%、18.9%、10.8%和10.8%（p<0.05）。STN阳性血清患者的总体生存概率更差。STN阴性与STN阳性患者的1年、2年、3年、4年和5年无进展生存率分别为90.4%、86.5%、76.9%、59.6%和51.9%，而STN阳性患者分别为35.1%、16.2%、8.1%、8.1%和5.4%（p<0.05）。STN阳性血清患者的总体无进展生存期较短。多因素回归分析显示，STN阳性、分期、PS和组织学分级是预测生存最重要的四个变量。这些结果表明，血清中STN抗原水平阳性是卵巢癌预后不良的独立预测指标。